ASND
Ascendis Pharma·NASDAQ
--
--(--)
--
--(--)
ASND fundamentals
Ascendis Pharma (ASND) Revenue Breakdown: Q3 2025 Business & Regional Performance
Ascendis Pharma (ASND) reported total revenue of 250.70M USD in Q3 2025, with its core business segment Sale of Commercial Products contributing 90.71%. Regionally, Europe remained the largest market, accounting for 17.65% of total revenue. Explore Ascendis Pharma's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
Ascendis Pharma (ASND) reported total revenue of 250.70M USD in Q3 2025, with its core business segment Sale of Commercial Products contributing 90.71%. Regionally, Europe remained the largest market, accounting for 17.65% of total revenue. Explore Ascendis Pharma's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What is the market's earnings forecast for Ascendis Pharma next quarter?What is the revenue and EPS growth rate for Ascendis Pharma year over year?Did Ascendis Pharma beat or miss consensus estimates last quarter?What is Ascendis Pharma's gross profit margin?What factors drove the changes in Ascendis Pharma's revenue and profit?What is Ascendis Pharma's latest dividend and current dividend yield?What guidance did Ascendis Pharma's management provide for the next earnings period?What does Ascendis Pharma do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
